PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20216337-0	2010	A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.	Carbamazepine	98-111	ATP binding cassette subfamily C member 2	Homo sapiens	29-33	
20216337-0	2010	A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.	Carbamazepine	98-111	ATP binding cassette subfamily C member 2	Homo sapiens	34-39	
20216337-2	2010	Therefore, genetic variations in the MRP2 gene may affect individual drug responses to the antiepileptic agent carbamazepine.	Carbamazepine	111-124	ATP binding cassette subfamily C member 2	Homo sapiens	37-41	
20216337-3	2010	METHODS: Associations between MRP2 polymorphisms and the adverse drug reactions (ADRs) of carbamazepine were analyzed using an integrated population genetics and molecular functional approach.	Carbamazepine	90-103	ATP binding cassette subfamily C member 2	Homo sapiens	30-34	
20216337-8	2010	Logistic regression analysis with multiple clinical variables indicated that the presence of A allele at the MRP2 c.1249G>A locus was an independent determinant of central nervous system ADR caused by carbamazepine.	Carbamazepine	204-217	ATP binding cassette subfamily C member 2	Homo sapiens	109-113	
20216337-10	2010	The functional study using ATPase assay and FACScan flow cytometer indicated that carbamazepine was a substrate of MRP2 and that the 417I variation selectively reduced carbamazepine transport across the cell membrane.	Carbamazepine	82-95	ATP binding cassette subfamily C member 2	Homo sapiens	115-119	
20216337-11	2010	CONCLUSION: These results strongly suggest that the A-allele of the MRP2 single nucleotide polymorphism c.1247G>A is associated with adverse neurological drug reactions to carbamazepine.	Carbamazepine	175-188	ATP binding cassette subfamily C member 2	Homo sapiens	68-72